跳至主要内容
临床试验/NCT00414323
NCT00414323已完成1 期

Evaluation of the Effects of Duloxetine on Norepinephrine Transporter Inhibition in Healthy Subjects

Eli Lilly and Company2 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2006年11月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
35
试验地点
2
主要终点
Concentrations of DHPG and NE in plasma (in sitting and standing positions), urine, and CSF after multiple daily doses (steady state).

研究概览

简要总结

The purpose of this study is to evaluate how taking duloxetine 60mg every day affects the transfer of two normal body chemicals, 3,4-dihydroxyphenylglycol (DHPG) and norepinephrine (NE), across cells in blood and cerebrospinal fluid.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Healthy subjects between the ages of 18-65 years are nonsmokers or are willing to refrain from smoking and are not taking concomitant medications which may inhibit or induce CYP1A2 or CYPD6 or is an MAOI.

排除标准

  • 未提供

结局指标

主要结局

Concentrations of DHPG and NE in plasma (in sitting and standing positions), urine, and CSF after multiple daily doses (steady state).

次要结局

  • Effect of duloxetine versus escitalopram on ex vivo reuptake inhibition of NE and F-hydroxytryptamine (5-HT) in serum and relationship to exposure.
  • Effect of duloxetine versus escitalopram on heart rate variability.
  • Ratio of duloxetine exposure in plasma to CSF at steady state.
  • Relationship between DHPG and NE concentrations and duloxetine exposure in CSF and plasma.

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验